bioRxiv Science⌕ Search

Biology subjects

Perez Saez, J. M.

Publications and source records attributed to Perez Saez, J. M..

2 recordsLinked to original sources

Galectin-1 Modulates Cell Adhesions, Caveolae, and Vascular Permeability in Kidney Endothelial Cells -- Insights from Proteomics, Phosphoproteomics, and Functional Studies

Microvascular inflammation and endothelial injury, triggered by interferon-gamma (IFN{gamma}), are hallmarks of antibody-mediated rejection (ABMR), the leading cause of premature kidney allograft loss. Glomerular extracellular matrix (ECM) remodeling and endothelial caveolae formation are important aspects of chronic ABMR. We found galectin-1, an immunomodulatory protein that interacts with the ECM, to be increased in the glomeruli of patients with ABMR, while its gene (LGALS1) expression was decreased by IFN{gamma} stimulation in glomerular endothelial cells. Mechanisms underlying endothelial dysfunction in ABMR, its links to ECM remodeling, and the role of immunomodulatory proteins such as galectin-1 remain incompletely understood. Here we studied the effects of galectin-1 modulation in glomerular microvascular endothelial cells (GMECs) in vitro. We demonstrated that galectin-1 was mainly expressed by glomerular endothelial cells in ABMR kidneys. To model key aspects of endothelial injury in ABMR, we knocked down LGALS1 in GMECs, followed by stimulation with IFN{gamma} and performed label-free quantitative proteomic and phosphoproteomic profiling of GMECs. Proteomic analysis identified 5446 proteins (FDR<0.01), of which 236, 827, and 267 were differentially expressed in response to LGALS1 knockdown, IFN{gamma} treatment, and their interaction, respectively (FDR<0.05). Both LGALS1 knockdown and the interaction between treatments significantly altered expression of adhesion proteins (FDR<0.01), particularly integrin subunit {beta}5, which was validated. Phosphoproteomic profiling identified 2727 phosphopeptides (FDR<0.01), with 28 that were differentially expressed across LGALS1 knockdown, IFN{gamma} treatment, and their interaction (P<0.01). Phosphorylation of CAVN1 and co-localization with its partner CAV1, critical for caveolar formation, were decreased in GMECs upon LGALS1 knockdown, IFN{gamma} stimulation, or both. In a microfluidic model of the glomerular microvasculature, addition of recombinant galectin-1 increased both endothelial permeability and secretion of proinflammatory cytokines, in LGALS1-silenced GMECs. Thus, endothelial signaling pathways regulated by inflammatory cues and galectin-1 contribute to endothelial injury and caveolae formation, highlighting galectin-1 as a potential therapeutic target in ABMR. SynopsisGalectin-1 is expressed by kidney glomerular endothelium. This study reveals that modifying galectin-1 in endothelial cells, in the presence of IFN{gamma} perturbs cytoskeletal, adhesion and caveolar proteins resulting in altered endothelial permeability. O_LILGALS1 knockdown increased ECM proteins and decreased interferon-induced proteins. C_LIO_LILGALS1 knockdown and IFN{gamma} treatment perturbed cell adhesion proteins such as ITGB5. C_LIO_LICAVN1 phosphorylation and colocalization with CAV1 decreased upon LGALS1 knockdown. C_LIO_LIExtracellular galectin-1 increased microvascular permeability in response to IFN{gamma}. C_LI

cell biology↗

A Developmental Lectin-Glycan Program Enables Early Breast Cancer Dissemination and Metastatic Onset

Early dissemination of breast cancer cells can precede clinically detectable tumor progression, yet the programs enabling this process, remain poorly understood. Here, we identify a developmental glycocheckpoint governed by the galectin-1 (GAL1)-glycan axis that is hijacked during early breast cancer dissemination. In the mammary gland, regulated GAL1 expression and glycan accessibility directed epithelial lineage specification and progesterone-induced branching morphogenesis. This program was aberrantly reactivated in early breast cancer lesions to promote epithelial plasticity, stem-like traits and metastatic competence. Mechanistically, GAL1 was enriched in mammary stem cell compartments and sustained progesterone receptor expression and activity. Genetic ablation or therapeutic inhibition of GAL1 across breast cancer models restrained early lesion progression, reduced circulating tumor cell frequency, and limited lung metastasis. Consistent with these findings, high GAL1 expression combined with low expression of the GAL1-restricting sialyltransferase ST6GAL1 was associated with poor clinical outcomes in patients. Thus, breast cancer co-opts a developmental GAL1-glycan program to disseminate early, revealing an unexpected link between mammary morphogenesis and metastatic progression and identifying GAL1 as a therapeutic vulnerability in early-stage disease.

cancer biology↗